-
CytomX Therapeutics NASDAQ:CTMX CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. CytomX is developing a novel class of investigational conditionally activated antibody therapeutics, based on its Probody® technology platform, for the treatment of cancer. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb.
Location: 151 Oyster Point Blvd Ste 400, California, 94080-1910, US | Website: www.cytomx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-39.51M
Cash
137.2M
Avg Qtr Burn
-21.45M
Short % of Float
9.42%
Insider Ownership
1.00%
Institutional Own.
72.47%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BMS-986288 (Anti-CTLA-4 non-fucosylated Probody) Details Colorectal cancer , Solid tumor/s | Phase 2 Data readout | |
CX-801 + KEYTRUDA Details Cancer, Solid tumor/s, Melanoma, Renal cell carcinoma, Head and neck squamous cell carcinoma | Phase 1a Data readout | |
CX-2051 (EpCAM expression) Details Cancer, Solid tumor/s | Phase 1a Data readout | |
CX-904 (EGFRxCD3) Details Cancer, Solid tumor/s | Phase 1a Update | |
CX-2029 (PDC directed against CD71) Details Non-small cell lung carcinoma, Head and neck squamous cell carcinoma, Cancer, Solid tumor/s | Failed Discontinued | |
BMS-986249 (CTLA-4-directed Probody therapeutic) Details Cancer, Melanoma | Failed Discontinued | |
Pacmilimab (CX-072) + CX-2009 (PD-L1 Targeting Probody Immunotherapy + CD166 PDC) Details Cancer, Triple-negative breast cancer | Failed Discontinued | |
Praluzatamab ravtansine (CX-2009) (anti-CD166) Details Cancer, HER2-expressing cancers, Breast cancer | Failed Discontinued |